Skip to Content

Millendo Technologies, Inc.

Merger

  • Date:
  • 5/4/2021
  • Company Name:
  • Millendo Technologies, Inc.
  • Stock Symbol:
  • MLND
  • Company Name - Buyer:
  • Tempest Therapeutics, Inc.
  • Status:
  • Investigating
  • Merger Announcement Date:
  • 3/29/2021

Case Finder

Locate any case using the tools below.

NEW YORK, May 4, 2021 – Bragar Eagel & Squire, P.C., a nationally recognized stockholder rights law firm, has launched an investigation into whether the board members of Millendo Technologies, Inc. (NASDAQ: MLND) breached their fiduciary duties or violated the federal securities laws in connection with the company’s merger with Tempest Therapeutics, Inc.

On March 29, 2021, Millendo announced that it had signed an agreement to merge with Tempest in an all-stock transaction.  Pursuant to the merger agreement, at the close of the merger current Millendo stockholders are expected to own approximately 18.5% of the combined company while current Tempest stockholders will own approximately 81.5%. The deal is scheduled to close in the first half of 2021.

Bragar Eagel & Squire is concerned that Millendo’s board of directors oversaw an unfair process and ultimately agreed to an inadequate merger agreement.  Accordingly, the firm is investigating all relevant aspects of the deal and is committed to securing the best result possible for Millendo’s stockholders.
 
The individual or institution below (“Plaintiff”) has reviewed and agrees to the Bragar Eagel & Squire, P.C. (“BESPC”) retainer agreement and authorizes BESPC to prosecute an action on Plaintiff’s behalf under the federal securities laws or applicable state laws to recover damages on behalf of investors in Millendo Technologies. BESPC will prosecute the action on a full contingency basis and will forward all costs and expenses.
 

Case Finder

Locate any case using the tools below.

You may share a link to this page on any of the sites listed below or send link via email: